American Association for Cancer Research
Browse
00085472can161901-sup-168905_1_supp_3698604_5f7gs9.pdf (421.64 kB)

Supplementary Tables 1, 2, 4, and 5 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer

Download (421.64 kB)
journal contribution
posted on 2023-03-31, 00:49 authored by Vikram B. Wali, Casey G. Langdon, Matthew A. Held, James T. Platt, Gauri A. Patwardhan, Anton Safonov, Bilge Aktas, Lajos Pusztai, David F. Stern, Christos Hatzis

Supplementary Table 1. Single doses selected for each drug from panel A. Supplementary Table 2. Layout of the two 384-well masterplates containing Panel B drugs. Supplementary Table 4. List of Top Synergistic Drug Combinations. Supplementary Table 5. Combination Index (CI) and Dose Reduction Index (DRI) values for the top drug combinations.

Funding

Breast Cancer Research Foundation

History

ARTICLE ABSTRACT

Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768 pairwise drug combinations in TNBC cell lines to identify synergistic combinations tractable to clinical translation. Medium-throughput results were scrutinized and extensively analyzed for sensitivity patterns, synergy, anticancer activity, and were validated in low-throughput experiments. Principal component analysis revealed that a fraction of all upregulated or downregulated genes of a particular targeted pathway could partly explain cell sensitivity toward agents targeting that pathway. Combination therapies deemed immediately tractable to translation included ABT-263/crizotinib, ABT-263/paclitaxel, paclitaxel/JQ1, ABT-263/XL-184, and paclitaxel/nutlin-3, all of which exhibited synergistic antiproliferative and apoptotic activity in multiple TNBC backgrounds. Mechanistic investigations of the ABT-263/crizotinib combination offering a potentially rapid path to clinic demonstrated RTK blockade, inhibition of mitogenic signaling, and proapoptotic signal induction in basal and mesenchymal stem–like TNBC. Our findings provide preclinical proof of concept for several combination treatments of TNBC, which offer near-term prospects for clinical translation. Cancer Res; 77(2); 566–78. ©2016 AACR.